药物排泄至唾液的预测:系统综述与理化性质分析
该系统综述纳入42项研究、40种药物,评估唾液-血浆浓度比与理化性质的关系。发现两性、碱性、酸性药物唾液-血浆比中位数相近(0.59、0.43、0.41),中性药物最低(0.21)。电离状态、蛋白结合、亲脂性、氢键供体数和极性表面积可部分预测唾液排泄。苯妥英、他克莫司、伏立康唑和拉莫三嗪可能适合唾液TDM。
要点
- 唾液-血浆比中位数:两性0.59、碱性0.43、酸性0.41、中性0.21。
- 酸性药物唾液排泄与低电离和蛋白结合相关(R²=0.85)。
- 苯妥英、他克莫司、伏立康唑、拉莫三嗪可能适合唾液TDM。
核心结论
- 许多常用药物可排泄至唾液,其排泄可部分由电离状态、蛋白结合、亲脂性、氢键供体数和极性表面积预测。
研究设计与样本
- 系统综述检索Medline、Web of Science和Embase(1974-2023)的人体临床研究,纳入至少10名受试者且每人至少5对唾液-血浆浓度的研究。
- 共纳入42项研究,涉及40种药物(抗精神病药、抗菌药、免疫抑制剂、抗血栓药、抗癌药和心脏药物)。
- 采用非随机干预研究偏倚风险工具评估研究质量,偏倚风险为低至中等。
主要发现
- 唾液-血浆比中位数:两性药物0.59、碱性药物0.43、酸性药物0.41、中性药物0.21。
- 酸性药物(n=5)唾液排泄较高与较低电离和蛋白结合相关,预测与观察唾液-血浆比相关性R²=0.85,p=0.02。
- 碱性药物(n=21)中pKa预测唾液排泄,Spearman相关系数R=0.53,p=0.02。
- 两性药物(n=10)中氢键供体数(R=-0.76,p=0.01)和极性表面积(R=-0.69,p=0.02)为预测因素。
- 中性药物(n=10)中蛋白结合(R=0.84,p=0.004)、亲脂性(R=-0.65,p=0.04)和氢键供体数(R=-0.68,p=0.03)为预测因素。
关键数值与推荐
- 通过Henderson-Hasselbalch方程调整蛋白结合和生理pH后预测唾液-血浆比。
- 认为可能适合唾液TDM的药物:苯妥英、他克莫司、伏立康唑和拉莫三嗪。
- 各药物类别Spearman相关分析显著性水平α=5%。
临床怎么用
- 临床可参考药物电离状态、蛋白结合、亲脂性、氢键供体数和极性表面积初步判断唾液TDM可行性。
- 苯妥英、他克莫司、伏立康唑和拉莫三嗪可考虑采用唾液替代血浆进行TDM。
- 唾液TDM结果解读需结合药物理化性质,避免直接外推血浆浓度。
局限性
- 药物转运体和生理因素对唾液排泄的贡献尚未评估,需进一步研究。
- 纳入研究数量有限,部分药物类别样本量小(如酸性药物n=5)。
- 研究偏倚风险为低至中等,可能影响结果稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Saliva is a patient-friendly matrix for therapeutic drug monitoring (TDM) but is infrequently used in routine care. This is due to the uncertainty of saliva-based TDM results to inform dosing. This study aimed to retrieve data on saliva-plasma concentration and subsequently determine the physicochemical properties that influence the excretion of drugs into saliva to increase the foundational knowledge underpinning saliva-based TDM. METHODS: Medline, Web of Science and Embase (1974-2023) were searched for human clinical studies, which determined drug pharmacokinetics in both saliva and plasma. Studies with at least ten subjects and five paired saliva-plasma concentrations per subject were included. For each study, the ratio of the area under the concentration-time curve between saliva and plasma was determined to assess excretion into saliva. Physicochemical properties of each drug (e.g. pKa, lipophilicity, molecular weight, polar surface area, rotatable bonds and fraction of drug unbound to plasma proteins) were obtained from PubChem and Drugbank. Drugs were categorised by their ionisability, after which saliva-to-plasma ratios were predicted with adjustment for protein binding and physiological pH via the Henderson-Hasselbalch equation. Spearman correlation analyses were performed for each drug category to identify factors predicting saliva excretion (α = 5%). Study quality was assessed by the risk of bias in non-randomised studies of interventions tool. RESULTS: Overall, 42 studies including 40 drugs (anti-psychotics, anti-microbials, immunosuppressants, anti-thrombotic, anti-cancer and cardiac drugs) were included. The median saliva-to-plasma ratios were similar for drugs in the amphoteric (0.59), basic (0.43) and acidic (0.41) groups and lowest for drugs in the neutral group (0.21). Higher excretion of acidic drugs (n = 5) into saliva was associated with lower ionisation and protein binding (correlation between predicted versus observed saliva-to-plasma ratios: R2 = 0.85, p = 0.02). For basic drugs (n = 21), pKa predicted saliva excretion (Spearman correlation coefficient: R = 0.53, p = 0.02). For amphoteric drugs (n = 10), hydrogen bond donor (R = - 0.76, p = 0.01) and polar surface area (R = - 0.69, p = 0.02) were predictors. For neutral drugs (n = 10), protein binding (R = 0.84, p = 0.004), lipophilicity (R = - 0.65, p = 0.04) and hydrogen bond donor count (R = - 0.68, p = 0.03) were predictors. Drugs considered potentially suitable for saliva-based TDM are phenytoin, tacrolimus, voriconazole and lamotrigine. The studies had a low-to-moderate risk of bias. CONCLUSIONS: Many commonly used drugs are excreted into saliva, which can be partly predicted by a drug's ionisation state, protein binding, lipophilicity, hydrogen bond donor count and polar surface area. The contribution of drug transporters and physiological factors to the excretion needs to be evaluated. Continued research on drugs potentially suitable for saliva-based TDM will aid in adopting this person-centred TDM approach to improve patient outcomes.
引用
- Nguyen TA, Chen RH, Hawkins BA, et al. Can we Predict Drug Excretion into Saliva? A Systematic Review and Analysis of Physicochemical Properties. Clin Pharmacokinet. 2024. PMID: 39008243. doi:10.1007/s40262-024-01398-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。